News | May 02, 2026
FDA grants breakthrough status to Laguna's mRNA blood test for schizophrenia diagnosis
The move puts a spotlight on one of psychiatry’s most persistent clinical challenges: misdiagnosis and delay
The move puts a spotlight on one of psychiatry’s most persistent clinical challenges: misdiagnosis and delay
The renewal covers two versions of the IQOS device and three HEETS tobacco variants
Patalganga plant received zero observation from USFDA earlier
The Puducherry facility, dedicated to Ibuprofen and its derivatives, is equipped with advanced infrastructure to serve both domestic and international markets
After Phase 3 results show major hair regrowth gains
The aim is to simplify and strengthen long-term control of airway disease through triple therapy in one device
The company receives approval for blood-based test enabling objective differentiation of schizophrenia and bipolar disorder
_256_384.png)
The company plans a phased expansion across India, focusing initially on metro cities and early-adoption hubs
The submission is backed by positive results from the Phase 3 AFFIRM study
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Gilenya Capsules, 0.5 mg of Novartis Pharmaceuticals Corporation (Novartis)
Subscribe To Our Newsletter & Stay Updated
